Biological product regulatory filing citing a New England Journal of Medicine paper — Autolus Therapeutics, 2025-01-13
Autolus TherapeuticsAutolus TherapeuticsNASDAQ AUTL
Filings SEC · Quote Yahoo cited a paper published in the New England Journal of Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the way it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was written in comparison to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, the report submitted to the Securities and Exchange Commission is called 8-K. The item number of the document submitted by Autolus Therapeutics on 2025-01-13 was 7.01 Reg FD public · 9.01 financial statements · attached documents. The company cited the paper published in New England Journal of Medicine in the attached press release. If you copy the sentence citing the paper verbatim from the original, it reads as follows.
Roddie C, et al "Obecabtagene autoleucel in B-cell acute lymphoblastic leukemia" N Engl J Med 2024; DOI: 10.1056/NEJMoa2406526 Deep molecular responses result in long term remissions in adult ALL • In all patients, the median OFS was 15.6 months • Lower disease burden at lymphodepletion was associated with better outcomes 1.
What readers should look at first is where the company placed the paper in the press release. Next, it is necessary to determine whether the paper supports the entire company's claim or only a part of it. To answer the latter question, one must read the full paper. This article, which reads only the abstract, cannot answer that.
The scope of the paper mentioned in the abstract is up to here.
The title of the paper is Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia and it was published in New England Journal of Medicine on 2024-11-27. The authors' affiliations are University College LondonUniversity College London
University · United Kingdom · Website Hospitals NHS Foundation Trust · University Hospitals Bristol NHS Foundation Trust · Newcastle upon Tyne Hospitals NHS Foundation Trust · University College London. The summary published at the beginning of the paper is called abstract. What this article has read is only up to there. This paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract through numerical comparison, so it is of a different grade from a full-text reading and a definitive judgment.
This is a phase 1b/2 trial of the CD19-targeting CAR-T therapy obecabtagene autoleucel administered to adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Of the 153 patients enrolled, 127 received one or more cell infusions, and the overall remission rate combining complete remission and remission with incomplete blood count recovery in the main group of 94 patients was 77%. This exceeded the pre-specified threshold of 40%, and the median follow-up period was 20 months. The survival and safety results are in the back of the abstract, which this text does not include.
The unanswered parts of the abstract remain in the main text and appendix. This text leaves the blanks as they are. Readers are to judge for themselves which sentences in the abstract correspond to the excerpts cited by the company, by comparing the two citations above.
One month later, the stock price was in the bottom quarter of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. Dates are counted in trading days, which are only the days the stock market is open. In calendar terms, 20 trading days is about a month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the filing | −9.4% | The extent of movement before the filing |
| On the filing date | −2.0% | On the filing date or the first trading day afterward |
| Cumulative over +1 to +5 trading days | −10.6% | One week |
| Cumulative over +1 to +20 trading days | −20.1% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of −20.1% in this case is in the bottom quarter, which is the 25% position from the bottom among 142 samples.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | Top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −6.9% | +5.5% | +19.5% | −20.1% |
Half of the sample falls between the two central marks on the chart. One checks the chart to see whether this case lies within or outside the range. The sample collects cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are past facts, not rules applicable to future cases.
After the filing, the company issued such documents.
Three 8-K filings issued by the company after the filing date are listed by item number only. In 8-K filings without titles, item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be determined by the number. The details of what occurred are read in the original text of each link.
- 2025-03-20 8-K Items 2.02, 7.01, 9.01 — Earnings announcement · Reg FD disclosure · Financial statements · Attached documents
- 2025-04-03 8-K Items 5.02, 9.01 — Executive/director changes · Financial statements · Attached documents
- 2025-04-23 8-K Items 7.01, 9.01 — Reg FD disclosure · Financial statements · Attached documents
What this article does not answer
This article, based only on abstracts, cannot answer what methods the paper used, what it reviewed, or how far it went. How many times the cited paper was referenced afterward can be verified again using OpenAlexOpenAlex
Data source · Website citation counts. What will be examined next is whether the company's next 8-K filing cites the same paper again.
Glossary
- 8-K
- A voluntary report submitted to the Securities and Exchange Commission when a U.S. listed company has news to inform shareholders. The type is indicated by item numbers such as earnings, contracts, and executive changes. All events in this article are derived from this document.
- Excess return
- The remainder after subtracting the overall market return from the stock return. It is used to observe the movement of the company alone by removing the portion where the market as a whole rises or falls.
- Trading day
- A date counting only the days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to about a month on the calendar.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full paper, one cannot know the details and limitations of the method.